Singapore, Sept. 22 -- Starpharma, an Australian biotechnology company, has announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma's proprietary DEP(R) drug delivery technology.

Starpharma will receive an upfront payment of $5.5 million (~AUD $8.3 million), and is eligible for development, commercial, and net sales milestones of up to $564 million (~AUD $855 million). In addition to this amount, Starpharma is eligible for tiered royalties on global net sales of products resulting from the collaboration.

The company will employ its proprietary DEP(R) platform technology to develop dendrimer-drug conjugates that incorporate ...